Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) stock soared 17.36% to $1.42 in the pre-market trading session following an announcement by a biopharmaceutical corporation focusing on advancing immunology-based treatments for common inflammatory disorders that two collaboration have been reached to explore potential therapeutic applications for its immunomodulatory drug, Ampion.
The Organization has entered into a cooperative study arrangement with the oldest and one of the top children’s hospitals in the United States, whereby both sides will partner and perform exploratory research to assess whether Ampion’s anti-inflammatory and signaling mechanisms could play a role in the treatment of certain rare pediatric inflammatory diseases.
